[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

L Zhong, Y Li, L Xiong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

[HTML][HTML] Comprehensive review of targeted therapy for colorectal cancer

YH Xie, YX Chen, JY Fang - Signal transduction and targeted therapy, 2020 - nature.com
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology

RJ Motzer, E Jonasch, N Agarwal, A Alva… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open …

RJ Motzer, T Powles, M Burotto, B Escudier… - The Lancet …, 2022 - thelancet.com
Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …

Management of metastatic clear cell renal cell carcinoma: ASCO guideline

WK Rathmell, RB Rumble… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma

TK Choueiri, T Powles, M Burotto… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …

Targeting the HIF2–VEGF axis in renal cell carcinoma

TK Choueiri, WG Kaelin Jr - Nature medicine, 2020 - nature.com
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

[HTML][HTML] Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

L Huang, S Jiang, Y Shi - Journal of hematology & oncology, 2020 - Springer
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor …

SK Pal, L Albiges, P Tomczak, C Suárez, MH Voss… - The Lancet, 2023 - thelancet.com
Background Immune checkpoint inhibitors are the standard of care for first-line treatment of
patients with metastatic renal cell carcinoma, yet optimised treatment of patients whose …

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman… - The Lancet …, 2021 - thelancet.com
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …